Role of Prucalopride in Chronic Constipation
Prucalopride is strongly recommended as a prescription therapy for adults with chronic idiopathic constipation who have failed over-the-counter laxatives, dosed at 2 mg once daily (or 1 mg daily in severe renal impairment). 1
Mechanism and Efficacy
Prucalopride is a highly selective serotonin 5-HT4 receptor agonist that stimulates colonic high-amplitude propagated contractions, promoting peristalsis and intestinal secretions. 1 The evidence supporting its use is robust:
- Increases complete spontaneous bowel movements (CSBMs) by approximately 1 additional CSBM per week compared to placebo (mean difference 0.96,95% CI 0.64-1.29) 1
- Responder rates are significantly higher: 165 more patients per 1,000 achieve ≥3 CSBMs per week (RR 2.37,95% CI 1.97-2.85) 1
- Quality of life improves with lower PAC-QOL scores (mean difference 0.32 lower, 95% CI 0.41-0.23 lower) 1
- Benefits appear within the first week and are sustained throughout treatment 2
The certainty of evidence is high for bowel frequency and responder rates, and moderate overall due to some imprecision around adverse event estimates. 1
Recommended Dosing
Standard adult dose: 2 mg once daily, taken with or without food 3
Dose adjustment required:
- Severe renal impairment (creatinine clearance <30 mL/min): Reduce to 1 mg once daily 1, 3
- Elderly patients (≥65 years): No dose adjustment needed; efficacy is comparable to younger adults 1, 4
Duration: Clinical trials evaluated 4-24 weeks of treatment, but the FDA label does not specify a maximum duration limit. 1 Prucalopride can be used as monotherapy or combined with over-the-counter agents. 1
Contraindications
Absolute contraindications 1, 3:
- Hypersensitivity to prucalopride (reactions include dyspnea, rash, urticaria, facial edema)
- Intestinal perforation or obstruction
- Obstructive ileus
- Crohn's disease
- Ulcerative colitis
- Toxic megacolon or megarectum
Safety Profile and Adverse Effects
Common adverse effects (occurring in ≥2% of patients) 3:
- Headache
- Abdominal pain
- Nausea
- Diarrhea
Important safety considerations:
- Most side effects are transient, occurring within the first week and typically resolving within days 1
- Diarrhea leading to discontinuation occurs at 3-fold higher rates than placebo (RR 3.00,95% CI 1.89-4.78), though absolute risk remains low 1
- Only 5% of patients discontinue due to adverse effects 1
- Cardiovascular safety: No increased cardiovascular adverse events compared to placebo 1
Critical warning - Suicidal ideation: The FDA label includes a boxed warning about potential suicidal ideation and behavior. 3 In a safety database of 4,476 subjects, 4 attempted suicides and 2 completed suicides occurred, though both completed suicides happened more than 1 month after discontinuing prucalopride. 1 A causal relationship has not been established, but clinicians must:
- Monitor patients for new or worsening depression
- Counsel patients and families to watch for unusual mood changes
- Instruct patients to discontinue immediately if suicidal thoughts emerge 3
Pregnancy and lactation: No drug-associated risks of miscarriage, major birth defects, or adverse maternal/fetal outcomes have been identified. 1
Clinical Algorithm for Use
Step 1: Confirm chronic idiopathic constipation diagnosis (≤2 spontaneous bowel movements per week for ≥3 months)
Step 2: Document failure of over-the-counter therapies (fiber, osmotic laxatives like polyethylene glycol, stimulant laxatives)
Step 3: Initiate prucalopride 2 mg once daily (1 mg if CrCl <30 mL/min)
Step 4: Assess response within 1-4 weeks (early response predicts sustained benefit) 2
Step 5: If partial response, consider combination therapy with:
- Osmotic laxatives (polyethylene glycol)
- Stimulant laxatives (bisacodyl, senna)
- These combinations are commonly used empirically when monotherapy fails 5
Step 6: Continue long-term if effective; no duration limit specified
Alternative Therapies
When prucalopride fails or is contraindicated, consider 5:
Other FDA-approved agents:
- Linaclotide or plecanatide (guanylate cyclase-C agonists)
- Both have demonstrated efficacy in patients unresponsive to over-the-counter laxatives 5
Off-label prescription options:
- Pyridostigmine (cholinesterase inhibitor): Particularly useful in autonomic neuropathy, diabetes-related constipation, or when combined with bisacodyl 5
- Tenapanor (sodium/hydrogen exchanger 3 inhibitor): FDA-approved for IBS-C, may be considered off-label 5
Stimulant laxatives: Chronic use is safe despite historical concerns; bisacodyl is particularly effective for increasing spontaneous bowel movements 5
Common Pitfalls to Avoid
- Don't withhold prucalopride in elderly patients: Efficacy is comparable across age groups 1, 4
- Don't forget dose reduction in severe renal impairment: This is mandatory, not optional 1
- Don't overlook pelvic floor dysfunction: If prucalopride fails, consider anorectal manometry or defecography to rule out dyssynergic defecation, which requires different management 5
- Don't discontinue too early: Benefits may take up to 4 weeks to fully manifest 2
- Don't ignore the psychiatric screening: While causality is unproven, baseline and ongoing assessment for depression/suicidal ideation is prudent 3